Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

MK5 Proteome Analysis

Table 3: Type II network, divided ranks. This table presents the output of the simulation of a type-II network in which we relied on the high confidence interactions and micro-array results. The output of the micro-array was then ranked and these ranks used as input into the network simulation. After performing two such simulations (one for the MK5 off and one for the MK5 on microarray output), we divided the ranks and sorted the results accordingly. The output of this technique is a collection of proteins that cluster naturally together.


Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description Value Type Network Comparison Type Interaction Map Filtered red green network_comparison
Results: HTML CSV LaTeX Showing element 2551 to 2600 of 3228 in total 
Value Type: Ranked
Network Comparison Type: Divided
Interaction Map: High confidence
Filtered: 1

\def\wcA{0.16666666666667\textwidth}
\def\wcB{0.16666666666667\textwidth}
\def\wcC{0.16666666666667\textwidth}
\def\wcD{0.16666666666667\textwidth}
\def\wcE{0.16666666666667\textwidth}
\begin{longtable}{|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2551\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
fructose-1,6-bisphosphatase isozyme 2 (ec 3.1.3.11) (d-fructose-1,6- bisphosphate 1-phosphohydrolase) (fbpase). [source:swissprot;acc:o00757]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
209.766\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
210.148\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00182\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2552\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
testis-specific chromodomain y protein 1. [source:swissprot;acc:q9y6f8]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
193.12\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
193.467\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.0018\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2553\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
chromodomain protein, y chromosome-like isoform a; cdy-like, autosomal; testis-specific chromodomain y-like protein. [source:refseq;acc:nm\_004824]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2554\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
testis-specific chromodomain protein y protein 2. [source:swissprot;acc:q9y6f7]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2555\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
s-adenosylmethionine synthetase gamma form (ec 2.5.1.6) (methionine adenosyltransferase) (adomet synthetase) (mat-ii). [source:swissprot;acc:p31153]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
212.953\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.572\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00179\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2556\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
chromodomain y-like protein 2. [source:refseq;acc:nm\_152342]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
193.119\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
193.46\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00177\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2557\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
elongation factor 2 (ef-2). [source:swissprot;acc:p13639]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
222.658\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
223.047\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00175\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2558\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
metabotropic glutamate receptor 2 precursor (mglur2). [source:swissprot;acc:q14416]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2559\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
metabotropic glutamate receptor 3 precursor (mglur3). [source:swissprot;acc:q14832]\vspace{3pt}}&&&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2560\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
monoglyceride lipase; lysophospholipase-like. [source:refseq;acc:nm\_007283]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
202.395\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
202.042\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2561\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
fructose-1,6-bisphosphatase (ec 3.1.3.11) (d-fructose-1,6-bisphosphate 1-phosphohydrolase) (fbpase). [source:swissprot;acc:p09467]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
209.825\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
210.18\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00169\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2562\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
glycogenin-1 (ec 2.4.1.186). [source:swissprot;acc:p46976]\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
208.429\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
208.779\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00168\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2563\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
adenosine kinase (ec 2.7.1.20) (ak) (adenosine 5'-phosphotransferase). [source:swissprot;acc:p55263]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2564\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
protein x 0001. [source:refseq;acc:nm\_016302]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2565\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
glycogenin-2 (ec 2.4.1.186) (gn-2) (gn2). [source:swissprot;acc:o15488]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2566\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
serine/threonine protein kinase 12 (ec 2.7.1.37) (aurora- and ipl1- like midbody-associated protein 1) (aim-1) (aurora/ipl1-related kinase 2) (aurora-related kinase 2) (stk-1) (aurora-b). [source:swissprot;acc:q96gd4]\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
219.907\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
220.267\vspace{3pt}}}&\multirow{6}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00164\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2567\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
kinesin-like protein kif23 (mitotic kinesin-like protein-1) (kinesin- like protein 5). [source:swissprot;acc:q02241]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2568\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
serine/threonine protein kinase 13 (ec 2.7.1.37) (aurora/ipl1/eg2 protein 2) (aurora/ipl1-related kinase 3) (aurora-c). [source:swissprot;acc:q9uqb9]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2569\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
serine/threonine kinase 6 (ec 2.7.1.37) (serine/threonine kinase 15) (aurora/ipl1-related kinase 1) (aurora-related kinase 1) (hark1) (aurora-a) (breast-tumor-amplified kinase). [source:swissprot;acc:o14965]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2570\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
cylindromatosis (turban tumor syndrome); cylindromatosis 1, turban tumor syndrome. [source:refseq;acc:nm\_015247]\vspace{3pt}}&&&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2571\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
protein-tyrosine phosphatase, non-receptor type 1 (ec 3.1.3.48) (protein-tyrosine phosphatase 1b) (ptp-1b). [source:swissprot;acc:p18031]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
209.549\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
209.205\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2572\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
transcription initiation factor tfiid 20/15 kda subunits (tafii- 20/tafii-15) (tafii20/tafii15). [source:swissprot;acc:q16514]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
203.953\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
204.285\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00163\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2573\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
peroxiredoxin 4 (ec 1.11.1.-) (prx-iv) (thioredoxin peroxidase ao372) (thioredoxin-dependent peroxide reductase a0372) (antioxidant enzyme aoe372) (aoe37-2). [source:swissprot;acc:q13162]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
213.347\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.005\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00161\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2574\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
swi/snf-related matrix-associated actin-dependent regulator of chromatin c1; mammalian chromatin remodeling complex brg1-associated factor 155; swi/snf complex 155 kda subunit; chromatin remodeling complex baf155 subunit. [source:refseq;acc:nm\_003074]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
220.016\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
219.667\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00159\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2575\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
protein-tyrosine phosphatase, non-receptor type 2 (ec 3.1.3.48) (t- cell protein-tyrosine phosphatase) (tcptp). [source:swissprot;acc:p17706]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
209.583\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
209.255\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00157\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2576\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
beta-1-syntrophin (59 kda dystrophin-associated protein a1, basic component 1) (dapa1b) (tax interaction protein 43) (tip-43) (syntrophin 2) (bsyn2). [source:swissprot;acc:q13884]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
213.422\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.75\vspace{3pt}}&\multirow{12}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00154\vspace{3pt}}}\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2577\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ca2+-dependent endoplasmic reticulum nucleoside diphosphatase; apyrase; soluble calcium-activated nucleotidase scan-1. [source:refseq;acc:nm\_138793]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
192.625\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
192.922\vspace{3pt}}&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2578\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
beta-2-syntrophin (59 kda dystrophin-associated protein a1, basic component 2) (syntrophin 3) (snt3) (syntrophin-like) (sntl). [source:swissprot;acc:q13425]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
213.422\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
213.75\vspace{3pt}}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2579\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
nitrilase 1. [source:refseq;acc:nm\_005600]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2580\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
utrophin (dystrophin-related protein 1) (drp1) (drp). [source:swissprot;acc:p46939]\vspace{3pt}}&&&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2581\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
dystrobrevin beta (beta-dystrobrevin) (dtn-b). [source:swissprot;acc:o60941]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
213.428\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.756\vspace{3pt}}&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2582\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial precursor (ec 2.3.1.-) (e2) (dihydrolipoamide branched chain transacylase) (bckad e2 subunit). [source:swissprot;acc:p11182]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
213.422\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.75\vspace{3pt}}&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2583\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
dystrobrevin alpha (dystrobrevin-alpha). [source:swissprot;acc:q9y4j8]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
213.415\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.743\vspace{3pt}}&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2584\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
dystrophin. [source:swissprot;acc:p11532]\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
213.422\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
213.75\vspace{3pt}}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2585\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
angiomotin. [source:refseq;acc:nm\_133265]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2586\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
angiomotin like 2; leman coiled-coil protein; angiomotin-like protein 2. [source:refseq;acc:nm\_016201]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2587\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
alpha-1-syntrophin (59 kda dystrophin-associated protein a1, acidic component 1) (pro-tgf-alpha cytoplasmic domain-interacting protein 1) (tacip1) (syntrophin 1). [source:swissprot;acc:q13424]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2588\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
60 kda heat shock protein, mitochondrial precursor (hsp60) (60 kda chaperonin) (cpn60) (heat shock protein 60) (hsp-60) (mitochondrial matrix protein p1) (p60 lymphocyte protein) (hucha60). [source:swissprot;acc:p10809]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
222.305\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
222.64\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00151\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2589\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
membrane protein expressed in epithelial-like lung adenocarcinoma. [source:refseq;acc:nm\_024792]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
212.74\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.422\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.0015\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2590\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
proteasome subunit alpha type 6 (ec 3.4.25.1) (proteasome iota chain) (macropain iota chain) (multicatalytic endopeptidase complex iota chain) (27 kda prosomal protein) (pros-27) (p27k). [source:swissprot;acc:p34062]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
214.605\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
214.287\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00148\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2591\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
polybromo 1. [source:refseq;acc:nm\_018165]\vspace{3pt}}&\multirow{6}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
220.02\vspace{3pt}}}&\multirow{6}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
219.696\vspace{3pt}}}&\multirow{6}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00147\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2592\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
swi/snf-related matrix-associated actin-dependent regulator of chromatin a5; sucrose nonfermenting-like 5. [source:refseq;acc:nm\_003601]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2593\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
possible global transcription activator snf2l4 (snf2-beta) (brg-1 protein) (mitotic growth and transcription activator) (brahma protein homolog 1). [source:swissprot;acc:p51532]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2594\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
possible global transcription activator snf2l1. [source:swissprot;acc:p28370]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2595\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
tbp-associated factor 172 (taf-172) (taf(ii)170). [source:swissprot;acc:o14981]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2596\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
possible global transcription activator snf2l2 (snf2-alpha). [source:swissprot;acc:p51531]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2597\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ran binding protein 11. [source:refseq;acc:nm\_016338]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
212.711\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.401\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00146\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2598\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
transcription initiation factor tfiid 100 kda subunit (tafii-100) (tafii100). [source:swissprot;acc:q15542]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
202.142\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
202.436\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00145\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2599\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ba207c16.2 (fragment). [source:sptrembl;acc:q9nql7]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
211.662\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
211.361\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00142\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2600\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
interferon-related developmental regulator 2 (skmc15 protein). [source:swissprot;acc:q12894]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
224.877\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
225.193\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00141\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/